Osimertinib with Chemotherapy in EGFR-Mutated NSCLC. Reply

David Planchard, Pasi A. Jänne, Kunihiko Kobayashi

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	478-479
Number of pages	2
Journal	New England Journal of Medicine
Volume	390
Issue number	5
DOIs	https://doi.org/10.1056/NEJMc2314600
Publication status	Published - 1 Feb 2024

Access to Document

@article{0dc40b31792140c4bc9a0037c8f37d49,

title = "Osimertinib with Chemotherapy in EGFR-Mutated NSCLC. Reply",

author = "David Planchard and J{\"a}nne, {Pasi A.} and Kunihiko Kobayashi",

year = "2024",

month = feb,

day = "1",

doi = "10.1056/NEJMc2314600",

language = "English",

volume = "390",

pages = "478--479",

journal = "New England Journal of Medicine",

issn = "0028-4793",

number = "5",

}

TY - JOUR

T1 - Osimertinib with Chemotherapy in EGFR-Mutated NSCLC. Reply

AU - Planchard, David

AU - Jänne, Pasi A.

AU - Kobayashi, Kunihiko

PY - 2024/2/1

Y1 - 2024/2/1

UR - http://www.scopus.com/inward/record.url?scp=85183809956&partnerID=8YFLogxK

U2 - 10.1056/NEJMc2314600

DO - 10.1056/NEJMc2314600

M3 - Letter

C2 - 38294984

AN - SCOPUS:85183809956

SN - 0028-4793

VL - 390

SP - 478

EP - 479

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 5

ER -